Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Baxter
Mallinckrodt
Express Scripts
Merck

Last Updated: January 26, 2023

CLINICAL TRIALS PROFILE FOR HYDROCHLOROTHIAZIDE; SPIRONOLACTONE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Hydrochlorothiazide; Spironolactone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed US Department of Veterans Affairs 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed VA Office of Research and Development 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00224549 ↗ PHARES Study: Management of Resistant Hypertension Completed Assistance Publique - Hôpitaux de Paris Phase 4 2005-04-01 The purpose of this study is to assess the efficacy of two different treatment regimens for treating resistant hypertension previously uncontrolled with at least 3 antihypertensive treatments. The study hypothesis is that these two regimens (one based on increasing diuretics and the other based on increasing renin angiotensin system blockage) may not differ in terms of efficacy.
NCT00515021 ↗ Diurnal Variation of Plasminogen Activator Inhibitor-1 Completed National Center for Research Resources (NCRR) Phase 4 2007-04-01 To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning administration.
NCT00515021 ↗ Diurnal Variation of Plasminogen Activator Inhibitor-1 Completed Vanderbilt University Medical Center Phase 4 2007-04-01 To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning administration.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Hydrochlorothiazide; Spironolactone

Condition Name

Condition Name for Hydrochlorothiazide; Spironolactone
Intervention Trials
Hypertension 4
Acute Heart Failure 1
Acute Kidney Injury 1
Blood Pressure 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Hydrochlorothiazide; Spironolactone
Intervention Trials
Hypertension 4
Metabolic Syndrome 1
Stroke 1
Heart Failure 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Hydrochlorothiazide; Spironolactone

Trials by Country

Trials by Country for Hydrochlorothiazide; Spironolactone
Location Trials
United States 12
Thailand 1
Puerto Rico 1
Japan 1
Poland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Hydrochlorothiazide; Spironolactone
Location Trials
Tennessee 2
Pennsylvania 1
Ohio 1
Mississippi 1
Iowa 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Hydrochlorothiazide; Spironolactone

Clinical Trial Phase

Clinical Trial Phase for Hydrochlorothiazide; Spironolactone
Clinical Trial Phase Trials
Phase 4 5
Phase 3 1
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Hydrochlorothiazide; Spironolactone
Clinical Trial Phase Trials
Completed 4
Recruiting 2
Active, not recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Hydrochlorothiazide; Spironolactone

Sponsor Name

Sponsor Name for Hydrochlorothiazide; Spironolactone
Sponsor Trials
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 1
Shanghai Jiao Tong University School of Medicine 1
US Department of Veterans Affairs 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Hydrochlorothiazide; Spironolactone
Sponsor Trials
Other 8
NIH 3
U.S. Fed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Mallinckrodt
McKesson
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.